Potential therapy for the Sudan strain of Ebola could help contain some future outbreaks

Aug 27, 2014
Potential therapy for the Sudan strain of Ebola could help contain some future outbreaks

Ebola is a rare, but deadly disease that exists as five strains, none of which have approved therapies. One of the most lethal strains is the Sudan ebolavirus (SUDV). Although not the strain currently devastating West Africa, SUDV has caused widespread illness, even as recently as 2012. In a new study appearing in the journal ACS Chemical Biology, researchers now report a possible therapy that could someday help treat patients infected with SUDV.

John Dye, Sachdev Sidhu, Jonathan Lai and colleagues explain that about 50-90 percent of ebola patients die after experiencing the typical symptoms of the disease, which include fever, muscle aches, vomiting and bleeding. Of the five known ebolaviruses, the Zaire (EBOV) and SUDV are the most deadly and cause the most recurring outbreaks. Many studies have focused on EBOV, the culprit of the current epidemic, but much less attention has been placed on SUDV until now. To develop a therapy for SUDV, this research team turned to an antibody that Dye's group previously reported.

The team's antibody was directed against SUDV and was made in mice. But the human immune system could potentially recognize that antibody as foreign and ultimately get rid of it, preventing the antibody from treating the disease. To avoid this situation, they wanted to make a "humanized" version of the antibody.

In the newly published work, the team put the ebola-specific part of the mouse antibody onto a scaffold and made some changes to this molecule. They identified two versions that were able to fend off SUDV in laboratory tests on cells and in specially bred mice. "These antibodies represent strong immunotherapeutic candidates for the treatment of SUDV infection," say the researchers.

This research, however, isn't expected to help with the current that, as of mid-August, has killed at least 1,200 people. That's because antibodies that kill off one strain of the virus haven't worked against other strains. The U.S. Food and Drug Administration—which has not yet approved any ebola therapies—did allow two U.S. aid workers infected during the current outbreak to be treated with an experimental drug, which is a cocktail of specifically targeting EBOV.

Explore further: Crucial research in development of promising Ebola virus treatment

More information: "Synthetic Antibodies with a Human Framework that Protect Mice from Lethal Sudan Ebolavirus Challenge" ACS Chem. Biol., Article ASAP
DOI: 10.1021/cb5006454

add to favorites email to friend print save as pdf

Related Stories

Seven things to know about Ebola

Aug 13, 2014

The death toll from the Ebola outbreak in West Africa has passed 1,000 and is still rising, according to the World Health Organization. Fear of the virus and concerns about its spread beyond Liberia, Guinea, ...

Beware fake ebola treatments on the internet, FDA says

Aug 15, 2014

(HealthDay)— As the death toll in the West Africa Ebola outbreak passes 1,000, the U.S. Food and Drug Administration is warning against products sold online that claim to treat the deadly disease or prevent ...

5 things to know about Ebola outbreak in W. Africa

Jul 28, 2014

(AP)—There has been panic and fear about the deadly Ebola disease spreading ever since Nigerian health officials reported Friday that a Liberian man sick with the disease had traveled to Togo and then Nigeria ...

Recommended for you

A refined approach to proteins at low resolution

3 hours ago

Membrane proteins and large protein complexes are notoriously difficult to study with X-ray crystallography, not least because they are often very difficult, if not impossible, to crystallize, but also because ...

Base-pairing protects DNA from UV damage

6 hours ago

Ludwig Maximilian University of Munich researchers have discovered a further function of the base-pairing that holds the two strands of the DNA double helix together: it plays a crucial role in protecting ...

User comments : 0